Shares of Aileron Therapeutics Inc (NASDAQ:ALRN) rose 2.8% during mid-day trading on Wednesday . The company traded as high as $2.22 and last traded at $2.18. Approximately 13,220 shares traded hands during trading, a decline of 96% from the average daily volume of 306,823 shares. The stock had previously closed at $2.12.
ALRN has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. ValuEngine downgraded shares of Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Finally, HC Wainwright initiated coverage on shares of Aileron Therapeutics in a report on Monday. They set a “buy” rating and a $7.00 price target on the stock.
The firm has a market capitalization of $27.73 million, a PE ratio of -1.08 and a beta of 3.18. The company has a current ratio of 4.23, a quick ratio of 4.23 and a debt-to-equity ratio of 0.19.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bridgeway Capital Management Inc. boosted its holdings in Aileron Therapeutics by 78.6% during the third quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock worth $312,000 after buying an additional 50,000 shares in the last quarter. Vanguard Group Inc boosted its holdings in Aileron Therapeutics by 8.0% during the third quarter. Vanguard Group Inc now owns 96,415 shares of the company’s stock worth $265,000 after buying an additional 7,109 shares in the last quarter. Parkwood LLC purchased a new stake in Aileron Therapeutics during the third quarter worth $149,000. Finally, Renaissance Technologies LLC acquired a new position in Aileron Therapeutics during the third quarter worth $137,000. 9.16% of the stock is currently owned by hedge funds and other institutional investors.
Aileron Therapeutics Company Profile (NASDAQ:ALRN)
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Recommended Story: Momentum Investing
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.